Docoh
Loading...

BEAM Beam Therapeutics

News

From Benzinga Pro
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
16 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) 2U (TWOU) Veracyte (VCYT) Beam Therapeutics (BEAM) Materialise (MTLS) Proto Labs (PRLB) TuSimple Holdings (TSP) Archer Aviation (ACHR) Velo3d (VLD) Splunk (SPLK) The Walt Disney
SVB Leerink Maintains Outperform on Beam Therapeutics, Lowers Price Target to $116
9 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $117 to $116.
Looking Into Beam Therapeutics's Return On Capital Employed
8 Nov 21
Earnings
Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a loss of $69.63 million.
Beam Therapeutics Q3 EPS $(0.42) Up From $(0.69) YoY
8 Nov 21
Earnings, News
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.42) per share. This is a 39.13 percent increase over losses of $(0.69) per share from the same period last year.
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Nov. 3, 2021
4 Nov 21
Hedge Funds, Trading Ideas, General
Zoom Video (ZM) Exact Sciences (EXAS) Twilio (TWLO) Robinhood (HOOD) UIPath (PATH) DraftKings (DKNG) Intellia Therapeutics (NTLA) Beam Therapeutics (BEAM) Teladoc (TDOC) NIU Technologies
Cathie Wood's ARK Invest Posts Fund Purchases For Tues, Nov. 2, 2021: Z, DKNG, PACB, TWOU, BEAM, KTOS, PATH, NIU, BLDE, MKFG, HOOD, GENI, ZM, CDNA, ADPT, EXAS, ALLO
3 Nov 21
Hedge Funds, Trading Ideas, General
Zillow Group (Z) - 288,813 DraftKings (DKNG) - 515,832 Pacific Biosciences of California (PACB) - 125,658 2U (TWOU) - 98,000 Beam Therapeutics (BEAM) - 1,442 Kratos
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 1, 2021: NTLA, BEAM, PATH, KTOS, VLD, NIU, BLDE, MKFG, ZM, GENI, EXAS, CDNA, ALLO, VERV, ARCT, ADPT, TWLO, HOOD, TOST
2 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) - 10,000 Beam Therapeutics (BEAM) - 10,000 UiPath (PATH) - 231,979 Kratos Defense & Security Solutions (KTOS) - 124,745 Velo3D (VLD)
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM
1 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) - 34,200 Pacific Biosciences of California (PACB) - 119,183 Archer Aviation (ACHR) - 591,618 MarkForged Holding Corp (MKFG) - 76,612 Blade Intellia Therapeutics (NTLA) - 34,200 Pacific Biosciences of California (PACB) - 119,183
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Oct. 25, 2021: TWTR, ROKU, PACB, BEAM, NNDM, SNAP, LPSN, SPOT, SKLZ, PD, ARCT, SLGC, NTLA, VERV, VCYT, PATH, DKNG, HOOD, AMZN, ETSY, PAGS, MKFG, DDD, BLDE, VLD
26 Oct 21
Hedge Funds, Trading Ideas, General
Twitter (TWTR) - 103,155 Roku (ROKU) - 12,731 Pacific Biosceiences of California (PACB) - 78,058 Beam Therapeutics (BEAM) - 7,638 Nano Dimension (NNDM)
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 22, 2021: TWTR, ROKU, BEAM, NTLA, VLD, SNAP, LPSN, SKLZ, PACB, SLGC, ARCT, VCYT, SURF
25 Oct 21
Hedge Funds, Trading Ideas, General
Twitter (TWTR) - 448,944 Roku (ROKU) - 16,743 Beam Therapeutics (BEAM) - 45,600 Intellia Therapeutics (NTLA) - 27,753 Velo3D (VLD) - 203467 Snap (SNAP)
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, Oct. 21, 2021: SKLZ, NTLA, SLGC, PACB, VCYT, ARCT, SURF
22 Oct 21
Hedge Funds, Trading Ideas, General
Skillz (SKLZ) - 2,112,856 Intellia Therapeutics (NTLA) - 28,280 Beam Therapeutics (BEAM) - 14,943 SomaLogic (SLGC) - 225,026 Pacific Biosciences of California (PACB)
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
19 Oct 21
Biotech, News, Health Care, Contracts, Movers, Trading Ideas, General
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Sana Biotechnology Says Obtains Non-Exclusive License To CRISPR Cas12b Gene Editing Technology From Beam Therapeutics To Enable Engineered Cell Programs
19 Oct 21
News, Contracts, FDA
Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with Beam Therapeutics Inc.
SVB Leerink Initiates Coverage On Beam Therapeutics with Outperform Rating, Announces Price Target of $117
19 Oct 21
News, Price Target, Initiation, Analyst Ratings
SVB Leerink analyst Rick Bienkowski initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Outperform rating and announces Price Target of $117.
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Oct. 12 2021: TDOC, CRSP, NTLA, SSYS, MKFG, BLDE, VLD, GENI, TWOU, CDNA, ARCT, SLGC, BEAM, QSI, DYNS
13 Oct 21
Hedge Funds, Trading Ideas, General
Teladoc Health (TDOC) - 198,681 Shares CRISPR Therapeutics (CRSP) - 61,732 Intellia Therapeutics (NTLA) - 13,254 Stratasys (SSYS) - 26,989 Markforged (MKFG) - 179,691 Blade Air Mobility (BLDE) - 94,782 Velo3D
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Oct. 11, 2021: TDOC, CRSP, NTLA, NIU, BLDE, MKFG, VLD, TWOU, GENI, BEAM, SLGC, CDNA, QSI, ACHR
12 Oct 21
Hedge Funds, Trading Ideas, General
Teladoc Health (TDOC) - 211,626 CRISPR Therapeutics (CRSP) - 248,148 Intellia Therapeutics (NTLA) - 37,991 Niu Technologies (NIU) - 159,329 Blade Air Mobility (BLDE)
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, Oct. 7, 2021: BEAM, SGFY, TWOU, SSYS, ACHR, BLDE, VLD, MKFG, NIU, TDOC, CND, GENI, SLGC, SURF, DYNS, QSI, PRNT
8 Oct 21
Hedge Funds, Trading Ideas, General
Beam Therapeutics (BEAM) - 85,469 Shares
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Oct. 6, 2021: DNA, PATH, SGFY, PACB, BEAM, SSYS, TWOU, BLDE, VLD, NIU, MKFG,, ACHR, TDOC, SQ, VUZI, ADPT, SLGC, SURF, QSI, DYNS, PRNT
7 Oct 21
Hedge Funds, Trading Ideas, General
Ginkgo Bioworks (DNA) - 8,264,233 Shares UiPath (PATH) - 580,632 SIgnify Health (SGFY) - 325,861 Pacific Biosciences Of California (PACB) - 57,511 Beam Therapeutics (BEAM) - 93,625 Stratasys (SSYS) - 77,800 2U
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Oct. 5, 2021: TDOC, PACB, BEAM, SGFY, TWOU, DNA, SSYS, MKFG, ACHR, BLDE, VLD, NIU, SQ, VUZI, ADPT, SURF, QSI, SLGC, MASS, DYNS, PATH, HOOD, TOST, PRNT
6 Oct 21
Hedge Funds, Trading Ideas, General
Teladoc Health (TDOC) - 154,175 Shares Pacific Biosciences Of California (PACB) - 783,580 Beam Therapeutics (BEAM) - 104,491 Signify Health (SGFY) - 749,117 2U (TWOU) - 166,427 Gingko Bioworks (DNA) -

Press releases

From Benzinga Pro
Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference
11 Nov 21
News, Press Releases
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results
8 Nov 21
Earnings, Press Releases
BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM),
Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors
8 Nov 21
News, Management, Press Releases
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Maraganore,
Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting
4 Nov 21
News, Health Care, Press Releases
Preclinical Data Demonstrates that BEAM-102 Makassar Base Editing Converts Sickle Hemoglobin to Functional Hemoglobin for Potential Treatment of Sickle Cell Disease New In Vivo Data Highlight Novel LNP Screening
Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
20 Oct 21
News, Press Releases
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
19 Oct 21
Press Releases
Agreement combines Beam's gene editing technology with Sana's ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered
Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation
19 Oct 21
Health Care, Analyst Ratings, Press Releases
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data
Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting
1 Oct 21
News, Health Care, Press Releases
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
28 Sep 21
News, Press Releases
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief
Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection
27 Sep 21
News, Health Care, Press Releases
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced preclinical data
Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues
23 Sep 21
News, Health Care, Press Releases, General
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data
Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
8 Sep 21
News, Press Releases
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief